_id
690f3d8dccc777a4e85d1ab6
Ticker
CERT
Name
Certara Inc
Exchange
NASDAQ
Address
4 Radnor Corporate Center, Radnor, PA, United States, 19087
Country
USA
Sector
Healthcare
Industry
Health Information Services
Currency
USD
Website
https://www.certara.com
Description
Certara, Inc., together with its subsidiaries, provides technology-enabled services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers solutions for model-informed drug development, as well as biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists working on pre-investigational new drug and translational stages; Simcyp Biopharmaceutics for formulation scientists; and Simcyp Secondary Intelligence that integrates toxicology with quantitative analysis of large networks of molecular and functional biological changes. It also provides Phoenix WinNonlin, a platform for non-compartmental analysis; Phoenix Hosted, that offers a secured and validated Certara Amazon Web Services workspace; Phoenix NLME; and Pirana Modeling Workbench, which provides modelers with a structure to facilitate the iterative processes. In addition, it offers Chemaxon JChem engines; Chemaxon Compound Registration, that supports a streamlined lead optimization process workflow; Chemaxon Design Hub, a design and tracking platform for drug discovery teams and their external collaborators; Certara D360 software, a scientific informatics system for small molecule and biologics discovery research; and Chemaxon Marvin, a chemical drawing tool. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange to define data standards and specifications; Metadata Repository that enables study design using controlled and standardized data; CoAuthor software, which creates and assembles regulatory submissions and medical publications; and GlobalSubmit, a submissions management software. Certara Inc. was founded in 2008 and is headquartered in Radnor, Pennsylvania.
Last Close
8.81
Volume
584513
Current Price
8.58
Change
-2.610669693530084
Last Updated
2025-11-29T11:19:50.503Z
Image
data:image/webp;base64,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
Ipo Date
2020-12-11T00:00:00.000Z
Market Cap
1458944000
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
0.765809090909091
Sentiment Sources
11
Rating
3.8182
Target Price
13.2083
Strong Buy
4
Buy
1
Hold
6
Sell
0
Strong Sell
0
Current Quarter
2025-09-30
Revenue
104616000
Cost Of Revenue
53700000
Gross Profit
50916000
Operating Expenses
44080000
Operating Income
6836000
Interest Expense
5011000
Pretax Income
-267000
Net Income
1525000
Eps
0.009495607643235638
Dividends Per Share
-
Shares Outstanding
159273367
Income Tax Expense
-1792000
EBITDA
23370000
Operating Margin
6.5343733272157225
Total Other Income Expense Net
-7103000
Cash
172711000
Short Term Investments
-
Receivables
98475000
Inventories
-
Total Current Assets
283303000
Property Plant Equipment
14217000
Total Assets
1535856000
Payables
3457000
Short Term Debt
3000000
Long Term Debt
290541000
Total Liabilities
471049000
Equity
1064807000
Depreciation
18769000
Change In Working Capital
3552000
Cash From Operations
32314000
Capital Expenditures
221000
Cash From Investing
-6792000
Cash From Financing
-14483000
Net Change In Cash
10445000
PE
130.8572
PB
1.2940869947323788
ROE
0.1432184424031773
ROA
0.09929316290068861
FCF
32093000
Fcf Percent
0.3067695190028294
Piotroski FScore
4
Health Score
70
Deep Value Investing Score
7
Defensive Investing Score
7
Dividend Investing Score
3
Economic Moat Investing Score
6.8
Garp Investing Score
4
Growth Investing Score
2.5
Momentum Investing Score
6
Net Net Investing Score
2.5
Quality Investing Score
5.5
Value Investing Score
6
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
104616000
Quarters > 0 > income Statement > cost Of Revenue
53700000
Quarters > 0 > income Statement > gross Profit
50916000
Quarters > 0 > income Statement > operating Expenses
44080000
Quarters > 0 > income Statement > operating Income
6836000
Quarters > 0 > income Statement > interest Expense
5011000
Quarters > 0 > income Statement > pretax Income
-267000
Quarters > 0 > income Statement > net Income
1525000
Quarters > 0 > income Statement > eps
0.009495607643235638
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
160600570
Quarters > 0 > income Statement > income Tax Expense
-1792000
Quarters > 0 > income Statement > EBITDA
23370000
Quarters > 0 > income Statement > operating Margin
6.5343733272157225
Quarters > 0 > income Statement > total Other Income Expense Net
-7103000
Quarters > 0 > balance Sheet > cash
172711000
Quarters > 0 > balance Sheet > short Term Investments
-
Quarters > 0 > balance Sheet > receivables
98475000
Quarters > 0 > balance Sheet > inventories
-
Quarters > 0 > balance Sheet > total Current Assets
283303000
Quarters > 0 > balance Sheet > property Plant Equipment
14217000
Quarters > 0 > balance Sheet > total Assets
1535856000
Quarters > 0 > balance Sheet > payables
3457000
Quarters > 0 > balance Sheet > short Term Debt
3000000
Quarters > 0 > balance Sheet > long Term Debt
290541000
Quarters > 0 > balance Sheet > total Liabilities
471049000
Quarters > 0 > balance Sheet > equity
1064807000
Quarters > 0 > cash Flow > net Income
1525000
Quarters > 0 > cash Flow > depreciation
18769000
Quarters > 0 > cash Flow > change In Working Capital
3552000
Quarters > 0 > cash Flow > cash From Operations
32314000
Quarters > 0 > cash Flow > capital Expenditures
221000
Quarters > 0 > cash Flow > cash From Investing
-6792000
Quarters > 0 > cash Flow > cash From Financing
-14483000
Quarters > 0 > cash Flow > net Change In Cash
10445000
Quarters > 0 > ratios > PE
0.009495607643235638
Quarters > 0 > ratios > PB
1.2940869947323788
Quarters > 0 > ratios > ROE
0.1432184424031773
Quarters > 0 > ratios > ROA
0.09929316290068861
Quarters > 0 > ratios > FCF
32093000
Quarters > 0 > ratios > Piotroski FScore
4
Quarters > 0 > ratios > fcf Percent
0.3067695190028294
Quarters > 0 > health Score
70
Quarters > 1 > quarter
2025-06-30
Quarters > 1 > income Statement > revenue
104570000
Quarters > 1 > income Statement > cost Of Revenue
40716000
Quarters > 1 > income Statement > gross Profit
63854000
Quarters > 1 > income Statement > operating Expenses
54302000
Quarters > 1 > income Statement > operating Income
9552000
Quarters > 1 > income Statement > interest Expense
4802000
Quarters > 1 > income Statement > pretax Income
6251000
Quarters > 1 > income Statement > net Income
-1968000
Quarters > 1 > income Statement > eps
-0.012229979013219296
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
160916057
Quarters > 1 > income Statement > income Tax Expense
8219000
Quarters > 1 > income Statement > EBITDA
29871000
Quarters > 1 > income Statement > operating Margin
9.134551018456536
Quarters > 1 > income Statement > total Other Income Expense Net
-3301000
Quarters > 1 > balance Sheet > cash
162266000
Quarters > 1 > balance Sheet > short Term Investments
-
Quarters > 1 > balance Sheet > receivables
106330000
Quarters > 1 > balance Sheet > inventories
-
Quarters > 1 > balance Sheet > total Current Assets
281393000
Quarters > 1 > balance Sheet > property Plant Equipment
14656000
Quarters > 1 > balance Sheet > total Assets
1543446000
Quarters > 1 > balance Sheet > payables
5477000
Quarters > 1 > balance Sheet > short Term Debt
7322000
Quarters > 1 > balance Sheet > long Term Debt
291170000
Quarters > 1 > balance Sheet > total Liabilities
472867000
Quarters > 1 > balance Sheet > equity
1070579000
Quarters > 1 > cash Flow > net Income
-1968000
Quarters > 1 > cash Flow > depreciation
18818000
Quarters > 1 > cash Flow > change In Working Capital
10716000
Quarters > 1 > cash Flow > cash From Operations
17842000
Quarters > 1 > cash Flow > capital Expenditures
64000
Quarters > 1 > cash Flow > cash From Investing
-6961000
Quarters > 1 > cash Flow > cash From Financing
-30694000
Quarters > 1 > cash Flow > net Change In Cash
-16820000
Quarters > 1 > ratios > PE
-0.012229979013219296
Quarters > 1 > ratios > PB
1.2896383817168093
Quarters > 1 > ratios > ROE
-0.1838257615738773
Quarters > 1 > ratios > ROA
-0.12750689042570976
Quarters > 1 > ratios > FCF
17778000
Quarters > 1 > ratios > Piotroski FScore
2
Quarters > 1 > ratios > fcf Percent
0.17001051926938893
Quarters > 1 > health Score
51
Quarters > 2 > quarter
2025-03-31
Quarters > 2 > income Statement > revenue
106004000
Quarters > 2 > income Statement > cost Of Revenue
41521000
Quarters > 2 > income Statement > gross Profit
64483000
Quarters > 2 > income Statement > operating Expenses
56860000
Quarters > 2 > income Statement > operating Income
7623000
Quarters > 2 > income Statement > interest Expense
4806000
Quarters > 2 > income Statement > pretax Income
4542000
Quarters > 2 > income Statement > net Income
4743000
Quarters > 2 > income Statement > eps
0.029395670384036243
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
161350292
Quarters > 2 > income Statement > income Tax Expense
-201000
Quarters > 2 > income Statement > EBITDA
27962000
Quarters > 2 > income Statement > operating Margin
7.191238066488056
Quarters > 2 > income Statement > total Other Income Expense Net
-3081000
Quarters > 2 > balance Sheet > cash
179086000
Quarters > 2 > balance Sheet > short Term Investments
-
Quarters > 2 > balance Sheet > receivables
105202000
Quarters > 2 > balance Sheet > inventories
-
Quarters > 2 > balance Sheet > total Current Assets
300175000
Quarters > 2 > balance Sheet > property Plant Equipment
15119000
Quarters > 2 > balance Sheet > total Assets
1561011000
Quarters > 2 > balance Sheet > payables
5068000
Quarters > 2 > balance Sheet > short Term Debt
3000000
Quarters > 2 > balance Sheet > long Term Debt
291798000
Quarters > 2 > balance Sheet > total Liabilities
476732000
Quarters > 2 > balance Sheet > equity
1084279000
Quarters > 2 > cash Flow > net Income
4743000
Quarters > 2 > cash Flow > depreciation
18614000
Quarters > 2 > cash Flow > change In Working Capital
-22688000
Quarters > 2 > cash Flow > cash From Operations
17352000
Quarters > 2 > cash Flow > capital Expenditures
5774000
Quarters > 2 > cash Flow > cash From Investing
-5774000
Quarters > 2 > cash Flow > cash From Financing
-13996000
Quarters > 2 > cash Flow > net Change In Cash
-97000
Quarters > 2 > ratios > PE
0.029395670384036243
Quarters > 2 > ratios > PB
1.2767797821040525
Quarters > 2 > ratios > ROE
0.43743353878475927
Quarters > 2 > ratios > ROA
0.30384154884238485
Quarters > 2 > ratios > FCF
11578000
Quarters > 2 > ratios > Piotroski FScore
4
Quarters > 2 > ratios > fcf Percent
0.10922229349835855
Quarters > 2 > health Score
61
Quarters > 3 > quarter
2024-12-31
Quarters > 3 > income Statement > revenue
100361000
Quarters > 3 > income Statement > cost Of Revenue
38263000
Quarters > 3 > income Statement > gross Profit
62098000
Quarters > 3 > income Statement > operating Expenses
56095000
Quarters > 3 > income Statement > operating Income
6003000
Quarters > 3 > income Statement > interest Expense
5004000
Quarters > 3 > income Statement > pretax Income
2180000
Quarters > 3 > income Statement > net Income
6577000
Quarters > 3 > income Statement > eps
0.04078363867320784
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
161265650
Quarters > 3 > income Statement > income Tax Expense
-4397000
Quarters > 3 > income Statement > EBITDA
25400000
Quarters > 3 > income Statement > operating Margin
5.981407120295732
Quarters > 3 > income Statement > total Other Income Expense Net
-3823000
Quarters > 3 > balance Sheet > cash
179183000
Quarters > 3 > balance Sheet > short Term Investments
-
Quarters > 3 > balance Sheet > receivables
119084000
Quarters > 3 > balance Sheet > inventories
1
Quarters > 3 > balance Sheet > total Current Assets
310852000
Quarters > 3 > balance Sheet > property Plant Equipment
16008000
Quarters > 3 > balance Sheet > total Assets
1575104000
Quarters > 3 > balance Sheet > payables
3502000
Quarters > 3 > balance Sheet > short Term Debt
8306000
Quarters > 3 > balance Sheet > long Term Debt
292425000
Quarters > 3 > balance Sheet > total Liabilities
516448000
Quarters > 3 > balance Sheet > equity
1058656000
Quarters > 3 > cash Flow > net Income
6577000
Quarters > 3 > cash Flow > depreciation
18216000
Quarters > 3 > cash Flow > change In Working Capital
13856000
Quarters > 3 > cash Flow > cash From Operations
49369000
Quarters > 3 > cash Flow > capital Expenditures
5836000
Quarters > 3 > cash Flow > cash From Investing
-97163000
Quarters > 3 > cash Flow > cash From Financing
-1303000
Quarters > 3 > cash Flow > net Change In Cash
-53840000
Quarters > 3 > ratios > PE
0.04078363867320784
Quarters > 3 > ratios > PB
1.3069961129961007
Quarters > 3 > ratios > ROE
0.6212594081552459
Quarters > 3 > ratios > ROA
0.4175597293892975
Quarters > 3 > ratios > FCF
43533000
Quarters > 3 > ratios > Piotroski FScore
4
Quarters > 3 > ratios > fcf Percent
0.43376411155727823
Quarters > 3 > health Score
70
Valuation > metrics > PE
130.8572
Valuation > metrics > PB
1.2940869947323788
Valuation > final Score
50
Valuation > verdict
211.7% Overvalued
Profitability > metrics > ROE
0.1432184424031773
Profitability > metrics > ROA
0.538292923124711
Profitability > metrics > Net Margin
0.014577120134587444
Profitability > final Score
4
Profitability > verdict
Weak
Risk > metrics > Debt Equity
0.44237969885622463
Risk > metrics > Interest Coverage
1.3641987627220116
Risk > final Score
65
Risk > verdict
High
Liquidity > metrics > Current Ratio
43.875329100201334
Liquidity > metrics > Quick Ratio
43.875329100201334
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
80
Prev Valuations > 1
100
Prev Valuations > 2
100
Prev Profitabilities > 0
0
Prev Profitabilities > 1
12
Prev Profitabilities > 2
17
Prev Risks > 0
68
Prev Risks > 1
66
Prev Risks > 2
65
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2025-12-14T00:19:38.087Z
Certara, Inc., together with its subsidiaries, provides technology-enabled services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers solutions for model-informed drug development, as well as biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists working on pre-investigational new drug and translational stages; Simcyp Biopharmaceutics for formulation scientists; and Simcyp Secondary Intelligence that integrates toxicology with quantitative analysis of large networks of molecular and functional biological changes. It also provides Phoenix WinNonlin, a platform for non-compartmental analysis; Phoenix Hosted, that offers a secured and validated Certara Amazon Web Services workspace; Phoenix NLME; and Pirana Modeling Workbench, which provides modelers with a structure to facilitate the iterative processes. In addition, it offers Chemaxon JChem engines; Chemaxon Compound Registration, that supports a streamlined lead optimization process workflow; Chemaxon Design Hub, a design and tracking platform for drug discovery teams and their external collaborators; Certara D360 software, a scientific informatics system for small molecule and biologics discovery research; and Chemaxon Marvin, a chemical drawing tool. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange to define data standards and specifications; Metadata Repository that enables study design using controlled and standardized data; CoAuthor software, which creates and assembles regulatory submissions and medical publications; and GlobalSubmit, a submissions management software. Certara Inc. was founded in 2008 and is headquartered in Radnor, Pennsylvania.
Stock Price
$ 0.00
0% decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/A(CERT) Movement as an Input in Quant Signal Sets news.stocktradersdaily.com
Read more →Showing 2 of 10
(Last Updated 2025-09-30)
Rating:
BUY
Target Price:
$13.2083
Analyst Picks
Strong Buy
4
Buy
1
Hold
6
Sell
0
Strong Sell
0
Sentiment:
Bullish
(Last Updated 2025-09-30)
Health Score
Price to Earnings Ratio (P/E)
-
Very Low
Low ≥ 50
High ≤ 10
Price to Book Ratio (P/B)
-
Very Low
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Very High
Low ≤ 5%
High ≥ 15%
Debt to Equity
-
High
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 91.18% of the total shares of Certara Inc
1.
Wasatch Advisors LP(8.4252%)
since
2025/06/30
2.
BlackRock Inc(8.3029%)
since
2025/06/30
3.
Vanguard Group Inc(7.7415%)
since
2025/06/30
4.
ArrowMark Colorado Holdings, LLC (ArrowMark Partners)(4.9118%)
since
2025/06/30
5.
Dimensional Fund Advisors, Inc.(4.8889%)
since
2025/06/30
6.
iShares Core S&P Small-Cap ETF(4.0861%)
since
2025/08/31
7.
Geneva Capital Management(3.807%)
since
2025/06/30
8.
Wasatch Core Growth(3.5402%)
since
2025/06/30
9.
Teacher Retirement System Of Texas(3.5328%)
since
2025/06/30
10.
Ameriprise Financial Inc(3.3996%)
since
2025/06/30
11.
Deerfield Management Co(2.4443%)
since
2025/06/30
12.
Vanguard Total Stock Mkt Idx Inv(2.3786%)
since
2025/07/31
13.
State Street Corp(2.2789%)
since
2025/06/30
14.
Vanguard Explorer Inv(2.1056%)
since
2025/06/30
15.
Morgan Stanley - Brokerage Accounts(1.9061%)
since
2025/06/30
16.
Vanguard Small Cap Index(1.8366%)
since
2025/07/31
17.
Brown Brothers Harriman & Co(1.7378%)
since
2025/06/30
18.
CT (Lux) American Smaller Com 9U USD(1.6562%)
since
2025/07/31
19.
Mackenzie Investments(1.6489%)
since
2025/06/30
20.
Capital World Investors(1.3448%)
since
2025/06/30
21.
American Funds SMALLCAP World A(1.3448%)
since
2025/06/30
22.
Wasatch Small Cap Growth Investor(1.2964%)
since
2025/06/30
23.
Canada Life US Small-Mid Cap Growth F(1.2584%)
since
2025/06/30
24.
Geode Capital Management, LLC(1.2562%)
since
2025/06/30
25.
Nationwide Geneva Small Cap Gr Instl Svc(1.2358%)
since
2025/07/31
26.
Royal Bank of Canada(1.1122%)
since
2025/06/30
27.
Vanguard Small Cap Growth Index Inv(1.0399%)
since
2025/07/31
28.
Massachusetts Financial Services Company(0.9964%)
since
2025/06/30
29.
CT American Smaller Coms(US) InstAccGBP(0.9466%)
since
2025/07/31
30.
Marshall Wace Asset Management Ltd(0.9415%)
since
2025/06/30
31.
Glenmede Trust Co NA(0.9181%)
since
2025/03/31
32.
London Company of Virginia(0.9169%)
since
2025/06/30
33.
DFA US Targeted Value I(0.8842%)
since
2025/07/31
34.
Meridian Growth Legacy(0.8218%)
since
2025/06/30
35.
DFA US Small Cap Value I(0.8021%)
since
2025/07/31
36.
Vanguard Institutional Extnd Mkt Idx Tr(0.7369%)
since
2025/07/31
37.
Vanguard VIF Small Co Gr(0.7074%)
since
2025/06/30
38.
Dimensional US Targeted Value ETF(0.6798%)
since
2025/08/29
39.
MFS New Discovery I(0.6759%)
since
2025/07/31
40.
iShares S&P Small-Cap 600 Value ETF(0.6396%)
since
2025/08/31
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
No earnings data available.
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.